Drugs / PPrV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01446926 | Sep 2011 → Mar 2013 | pneumococcal infection, pneumonia | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PPrV | “Here, we examined the safety and immunogenicity of a trivalent recombinant PPrV containing PcpA, PhtD, and PlyD1.” PMID 26143615 ↗ Jul 2015 |
| Modality | Vaccine | “trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine” PMID 26143615 ↗ Jul 2015 |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT01446926 ↗ |